HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
A phase 3 trial testing Clifutinib in acute myeloid leukaemia, now recruiting.
Overview
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML is a phase 3 interventional study registered as NCT05586074, led by Sunshine Lake Pharma, and recruiting when checked on 2026-09-11. Official title: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia: a Multicenter, Open-label, Randomised Phase 3 Trial. Planned enrolment is 324 participants (estimated). The study started in 2023-03-03 and primary completion is expected in 2027-11-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TrialA Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentCART84
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentBleximenib
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentCusatuzumab
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentHMPL-306
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentAK117
Shares Acute myeloid leukaemia and the tag ctgov-ingest.